EU/3/12/1026: Orphan designation for the treatment of calciphylaxis
Table of contents
On 17 July 2012, orphan designation (EU/3/12/1026) was granted by the European Commission to Sanifit Laboratoris, S.L., Spain, for hexasodium phytate for the treatment of calciphylaxis.
In October 2015, Sanifit Laboratoris, S.L. changed name to Laboratoris Sanifit S.L. In April 2021, Laboratoris Sanifit S.L. changed name to Sanifit Therapeutics S.A.
Treatment of calciphylaxis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|November 2022||The sponsorship was transferred from Sanifit Therapeutics S.A., Spain to Vifor France, France, in November 2022.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: